论文部分内容阅读
目的 关于慢性乙型肝炎患者接受核苷类似物实施抗病毒治疗发生耐药停药之后的临床分析。方法 对2018年3月至2021年3月到我院接受治疗的10例确诊为慢性乙型肝炎患者的临床资料进行回顾性分析，所有患者均接受核苷类似物治疗，并因出现耐药而擅自停药。对所有患者停药之后的临床表现、实验室检查结果、内科保守治疗、预后等情况进行统计。结果 ①停药以后，患者的丙酸转氨酶（ALT）、天冬氨酸转氨酶（AST）均出现升高，白蛋白、凝血酶活动度（PTA）均下降，病毒定量升高，差异有统计学意义（P＜0.05）。②停药后，患者的e“,”Objective To analyze the clinical analysis of patients with chronic hepatitis B who received nucleoside analogues for antiviral therapy and drug resistance was discontinued. Methods The clinical data of 10 patients diagnosed with chronic hepatitis B who were treated in our hospital from March 2018 to March 2021 were retrospectively analyzed. All patients received nucleoside analog therapy and were affected by drug resistance. Stop the drug without authorization. Statistics on the clinical manifestations， laboratory test results， conservative medical treatment， and prognosis of all patients after drug withdrawal. Results (1)After the drug was stopped， the patient\'s alanine aminotransferase (ALT) and aspartate aminotransferase (AST) all increased，albumin and thrombin activity (PTA) all decreased， and the virus quantification increased. The difference was statistically significant (P＜0.05); (2)After the drug was stopped， the patient\'s e antigen was positive. After treatment， 1 patient died， and the liver function of the rest of the patients recovered well; (3)The same period of time when the patients were admitted to chronic hepatitis B and received nucleosides similar In 135 patients treated with antiviral drugs， the incidence of drug resistance was 7.41%. Through single-factor analysis of variance， it was found that: non-compliance with the doctor\'s prescription， viral genotype drug resistance mutation， unreasonable medication regimen， intermittent treatment， combined drug liver ， Shorter course of treatment， etc. is a single factor for drug resistance in patients with chronic hepatitis B receiving nucleoside analogue antiviral therapy， and the difference is statistically significant (P＜0.05); (4) Logistic multivariate regression analysis can be obtained ， virus genotype drug resistance mutations， non-compliance with doctors\' medication，combined drug liver are independent risk factors for drug resistance in patients with chronic hepatitis B receiving nucleoside analog antiviral therapy， and the difference is statistically significant (P＜0.05). Conclusion Patients with chronic hepatitis B receiving nucleoside analogues for antiviral therapy have many factors leading to drug resistance. Discontinuation of drug resistance after drug resistance occurs will lead to aggravation of liver damage， and patients will have severe hepatitis， which increases the risk of death. Surviving patients also have manifestations of disease progression， which should be paid attention to.